Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
Authors
Keywords
-
Journal
Vaccines
Volume 9, Issue 6, Pages 623
Publisher
MDPI AG
Online
2021-06-09
DOI
10.3390/vaccines9060623
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
- (2021) Dhruv Bansal et al. Cancers
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
- (2021) Marijo Bilusic et al. Journal for ImmunoTherapy of Cancer
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
- (2020) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Revisiting Immunotherapy: A Focus on Prostate Cancer
- (2020) Ha-Ram Cha et al. CANCER RESEARCH
- Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma
- (2020) Robert A. Figlin et al. CLINICAL CANCER RESEARCH
- Association of putative activated CD8+ T cells with modulation of rising serum PSA levels in biochemically relapsed prostate cancer patients using immunotherapy targeting prostate tumor-associated antigens: a Phase 1 study
- (2020) Neal D. Shore et al. MOLECULAR THERAPY
- T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
- (2020) Aleksandar Z. Obradovic et al. CLINICAL CANCER RESEARCH
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
- (2020) Christos E. Kyriakopoulos et al. CLINICAL CANCER RESEARCH
- The immunology of renal cell carcinoma
- (2020) C. Marcela Díaz-Montero et al. Nature Reviews Nephrology
- Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
- (2020) Federica Cappuccini et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
- (2019) Harm Westdorp et al. Journal for ImmunoTherapy of Cancer
- Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
- (2019) Douglas G. McNeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Present status and future perspective of peptide-based vaccine therapy for urological cancer
- (2018) Wataru Obara et al. CANCER SCIENCE
- Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
- (2018) Masanori Noguchi et al. CANCER SCIENCE
- Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).
- (2018) Justine Ku et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
- (2018) Masahiro Ogasawara et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
- (2018) Douglas G. McNeel et al. Oncotarget
- Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers
- (2018) Laura Mercatali et al. Jove-Journal of Visualized Experiments
- Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
- (2018) Patrick A. Ott et al. CANCER RESEARCH
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
- (2018) Jason M. Redman et al. Journal for ImmunoTherapy of Cancer
- Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma
- (2017) Takafumi Minami et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
- (2017) Farhad Fakhrejahani et al. JOURNAL OF CLINICAL ONCOLOGY
- Management and potentialities of primary cancer cultures in preclinical and translational studies
- (2017) Giacomo Miserocchi et al. Journal of Translational Medicine
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder
- (2016) W Obara et al. ANNALS OF ONCOLOGY
- Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma
- (2016) Wataru Obara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer
- (2016) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle–Invasive Bladder Cancer Patients
- (2016) Laurent Derré et al. CLINICAL CANCER RESEARCH
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
- (2016) Emmanuel S. Antonarakis et al. CLINICAL CANCER RESEARCH
- A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer
- (2016) Kazuhiro Yoshimura et al. EUROPEAN UROLOGY
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
- (2016) E. Scheid et al. Cancer Immunology Research
- Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
- (2016) Ioannis F. Voutsas et al. Journal for ImmunoTherapy of Cancer
- Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
- (2015) Hai-Bo Xi et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients
- (2015) Hiromitsu Araki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression
- (2015) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
- (2015) Eleftheria A. Anastasopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
- (2015) E. J. Small et al. CLINICAL CANCER RESEARCH
- An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
- (2015) M. Noguchi et al. CLINICAL CANCER RESEARCH
- Identification of Programmed Death Ligand 1–derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma
- (2015) Takafumi Minami et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment
- (2015) KEI FUJIO et al. ONCOLOGY REPORTS
- Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)
- (2015) Douglas G McNeel et al. Human Vaccines & Immunotherapeutics
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
- (2015) Hubert Kübler et al. Journal for ImmunoTherapy of Cancer
- AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction
- (2014) Sonia A. Perez et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies
- (2014) Ira Surolia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A Phase I/Ib Study of Folate Immune (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) With Interferon-α and Interleukin-2 in Patients With Renal Cell Carcinoma
- (2014) Robert J. Amato et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Antigen-specific vaccines for cancer treatment
- (2014) Maria Tagliamonte et al. Human Vaccines & Immunotherapeutics
- Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer
- (2013) Xiaoliang PANG et al. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
- Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
- (2013) K Yoshimura et al. BRITISH JOURNAL OF CANCER
- AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
- (2013) Sonia A. Perez et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer
- (2013) Daniela Fenoglio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer
- (2013) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial
- (2013) Richard Harrop et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
- (2013) Toshiaki Tanaka et al. Clinical & Developmental Immunology
- Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy
- (2013) Ritika Jaini et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
- (2013) J. Vuky et al. ONCOLOGIST
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
- (2013) Benedetto Farsaci et al. Journal for ImmunoTherapy of Cancer
- Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)
- (2012) Richard Harrop et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time
- (2012) Lindsey Chudley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Technologies for enhanced efficacy of DNA vaccines
- (2012) Fadi Saade et al. Expert Review of Vaccines
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy
- (2012) M Kamrava et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer
- (2012) Susan F. Slovin et al. VACCINE
- Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer
- (2012) Tetsuro Sasada et al. Human Vaccines & Immunotherapeutics
- Tumor vaccination using messenger RNA: prospects of a future therapy
- (2011) Sebastian Kreiter et al. CURRENT OPINION IN IMMUNOLOGY
- CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer
- (2011) Michael A Morse et al. Expert Review of Vaccines
- Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy
- (2011) Masanori Noguchi et al. PROSTATE
- A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin
- (2010) Kazumasa Matsumoto et al. BJU INTERNATIONAL
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
- (2010) Stéphane Oudard et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
- (2010) J. Karbach et al. CLINICAL CANCER RESEARCH
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer
- (2010) Richard J Sylvester INTERNATIONAL JOURNAL OF UROLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)
- (2009) Robert J. Amato et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search